B 701

Drug Profile

B 701

Alternative Names: B701

Latest Information Update: 19 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioClin Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Type 3 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Bladder cancer
  • Phase I Multiple myeloma; Solid tumours; Urogenital cancer
  • Preclinical Achondroplasia

Most Recent Events

  • 26 Jun 2017 Dana Farber Cancer Institute terminates a phase I trial in Bladder cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT02925533)
  • 02 Jun 2017 Topline adverse events and efficacy data from a phase I/II trial in Bladder cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 03 May 2017 Phase-I clinical trials in Urogenital cancer (Monotherapy, Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT03123055)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top